Celltrion Allies With Rani As Exclusive Oral Ustekinumab Partner
Rani/Celltrion Suggest Potential To Broaden Partnership In Future
Having previously an agreement with BioFactura to assess the company’s proposed ustekinumab biosimilar with its RaniPill oral drug delivery technology, Rani has now unveiled a deal with Korean major Celltrion for use of its CT-P43 Stelara biosimilar candidate.
You may also be interested in...
As biosimilars to Stelara (ustekinumab) continue to advance in global markets, Rani Therapeutics has made progress for its proposed RT-111 orally administered ustekinumab biosimilar.
Celltrion has become the latest biosimilars developer to announce a deal with J&J allowing it to launch a US ustekinumab biosimilar in early 2025. The Korean firm anticipates US FDA approval next year for its CT-P43 version.
Celltrion has doubled down on its alliance with Rani Therapeutics for oral pill versions of biosimilars by adding adalimumab to an existing collaboration covering ustekinumab.